Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1998-03-12
1999-03-23
Wax, Robert A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 13, 514 14, 514 15, 530324, 530325, 530326, 530327, A61K 3808, A61K 3810, C07K 706, C07K 708
Patent
active
058859659
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
The family of naturally occurring human histatins is a group of twelve low molecular weight, abundant in histidine, peptides found in human submandibular and parotid salivary secretions (Oppenheim et al. (1986), J. Biol. Chem. 261: 1177-1182; Oppenheim et al. (1988), J. Biol. Chem. 263: 7472-7477; Troxler et al. (1990), J. Dent. Res. 69: 2-6). The primary structure of the major family members (histatins 1, 3, and 5; 70-80% of the whole family) has shown that these proteins consist of 38, 32 and 24 amino acid residues, respectively. There is a high degree of homology among these three major histatins. Histatin 5 results from post-translational cleavage of histatin 3. Many of the smaller members of the histatin family may also, in fact, originate by post-translational proteolysis of histatins 1, 3 and 5 (Oppenheim et al. (1989), Human Saliva: Clinical Chemistry and Microbiology Vol. 1 CRC Press, Boca Raton, Fla., ed. Tenovuo, J. O.; Lal et al. (1992), Arch. Oral Biol. 37: 7-13). The genes that encode histatins 1 and 3 have been localized chromosomally (vanderSpek et al., (1989), Am. J. Hum. Genet. 45: 381-387) and sequenced (Sabatini, L. M. et al. (1989), Biochem. Biophys. Res. Comm. 160:495-502). Histatins 1 and 3 appear to be derived from separate genes.
The three major human histatins exhibit specific antimicrobial activities towards diverse oral microbiota. These histatins, at physiological concentrations, are capable of killing Candida albicans in both blastopore and mycelial forms (Pollock, J. J. et al. (1984), Infect. Immun. 44:702-707; Xu, T. et al. (1991), Infect. Immun. 59 (8): 2549-2554). Histatins are also capable of killing oral bacteria, including Streptococcus mutans (MacKay, B. J. et al. (1984), Infect. Immun. 44:695-701; Xu, T. et al. (1990), J. Dent. Res. 69: 239), Porphyromonas gingivalis (Colon et al. (1993), J. Dent. Res. 72: 322) and Actinomyces viscosus (Kalpidis et al. (1992) J. Dent. Res. 72: 305).
Infection with the yeast Candida albicans is a prevalent and, in some cases, life-threatening condition affecting otherwise healthy and immuno-compromised patients. Candidal vaginitis is estimated to affect 15 to 55% of healthy young women. Candidal infections often occur in diabetics, during pregnancy, and following medication with antibiotics, steroid hormones, or oral contraceptives. (Tapper-Jones, L. M. et al. (1981) J. Clin. Pathol. 34:706-11; Sobel, J. D. et al. (1984) Infect. Immun. 44:576-580). Oral candidiasis is an early opportunistic infection of Acquired Immune Deficiency Syndrome (AIDS) in individuals infected with human immunodeficiency virus type 1, as well as a complication of radiation and chemotherapy in cancer patients. (Yeh, C. -K. et al. (1988) J. of Acquired Immune Deficiency Syndromes 1:361-366). In addition, candidal infection of denture wearers plays a primary role in dental stomatitis, a prevalent oral problem among the elderly. (Pollock, J. J. et al. (1990) NYS Dental J. 56:36-38). Candidal infections of skin and urethra are widespread problems. In patients in intensive care and immuno-compromised patients, systemic fungal infection often leads to death, since there are few safe and effective anti-fungal pharmaceuticals for intravenous use. (Burnie, J. P. et al. (1985) British Medical Journal 290:746-748). Similarly, infections with various bacterial species can cause severe disease states and even death.
Although several anti-fungal agents (e.g., clotrimazole, miconazole, ketoconazole, and nystatin) and anti-bacterial agents (penicillin, streptomycin, tetracycline and chlorhexidine) are currently available, these agents are not completely effective, can lead to drug resistant organisms and can produce adverse side effects. Many are not appropriate for oral or systemic administration. Thus, a potent, naturally occurring anti-fungal or anti-bacterial substance would provide a significant improvement in the treatment of microbial infection.
SUMMARY OF THE INVENTION
This invention is based on substantially pure peptides which have ant
REFERENCES:
patent: 4725576 (1988-02-01), Pollock et al.
patent: 4734400 (1988-03-01), Bolin et al.
patent: 4962277 (1990-10-01), Cuervo et al.
patent: 5032574 (1991-07-01), Wilde et al.
patent: 5190920 (1993-03-01), Eyal et al.
patent: 5221732 (1993-06-01), Chen et al.
patent: 5225399 (1993-07-01), Zasloff et al.
patent: 5239059 (1993-08-01), Zasloff et al.
patent: 5304633 (1994-04-01), Tomita et al.
patent: 5324716 (1994-06-01), Selsted et al.
patent: 5409898 (1995-04-01), Darveau et al.
patent: 5424290 (1995-06-01), Maloy et al.
patent: 5447914 (1995-09-01), Travis et al.
patent: 5459237 (1995-10-01), Berkowitz et al.
patent: 5464823 (1995-11-01), Lehrer et al.
patent: 5470950 (1995-11-01), Maloy et al.
patent: 5486503 (1996-01-01), Oppenheim et al.
patent: 5504190 (1996-04-01), Houghton et al.
patent: 5519115 (1996-05-01), Mapelli et al.
patent: 5547939 (1996-08-01), Selsted
patent: 5549894 (1996-08-01), Hunt
patent: 5631823 (1997-05-01), Oppenheim et al.
patent: 5646119 (1997-07-01), Oppenheim et al.
patent: 5652332 (1997-07-01), Little, II
patent: 5688767 (1997-11-01), Hancock et al.
patent: 5693486 (1997-12-01), Lehrer et al.
patent: 5708145 (1998-01-01), Lehrer et al.
Sugiyama, K., et al., Japanese Journal of Oral Biology, vol. 27, "The amino acid sequence of a salivary peptide (F-A) with histamine-releasing properties", pp. 1252-1253, 1985.
Sabatini, L. M., et al., Biochemical and Biophysical Research Communications, vol. 160, "Histatins, a family of salivary histidine-rich proteins are encoded by at least two loci (HIS1 and HIS2)", pp. 495-502, 1989.
Sugiyama, K., et al., Archives of Oral Biology, vol. 35, "Rapid purification and characterization of histatins (histidine-rich polypeptides) from human whole slaiva", pp. 415-419, 1990.
VanderSpek, J. C., et al., Archives of Oral Biology, vol. 35, "Molecular cloning of human submandibular histatins", pp. 137-143, 1990.
Wade, R., et al., Proceedings of the National Academy of Sciences, U.S.A., vol. 87, "All -D-amino acid-containing channels forming antibiotic peptides", pp. 476-4765, 1990.
Bessalle, R., et al., FEBS Letters, vol. 274, "All-D-magainin: Chirality, antimicrobial activity and proteolytic resistance", pp. 151-155, 1990.
Chang, C. C., et al., in PEPTIDES 1990, Giralt, E., et al., Eds., "Synthesis and biological activity of histidine-rich peptides bonded to polylysine backbone", pp. 843-846, ESCOM, Pub. Leiden, 1991.
Lai, k., et al., Archives of Oral Biology, vol. 37, "The use of capillary electrophoresis to identify cationid proteins in human parotid saliva", pp. 7-13, 1992.
Sabatini, L. M., et al., Molecular Biology and Evolution, vol. 10, "Nucleotide sequence anlaysis of the human salivary proteins genes HLS1 and HLS2 and evolution of the STATH/HIS gene family", pp. 497-511, 1993.
Richardson, C. F., et al., Archives of Oral Biology, vol. 38, "The influence of histatin-5 fragments on the mineralization of hydroxyapatite," pp. 997-1002, 1993.
Driscoll, J., et al., Gene, vol. 177, "Candidacidal activity of human salivary histatin recombinant variants produced by site-directed mutagenesis", pp. 29-34, 1996.
Tsai, H., et al., Infection and Immunity, vol. 64, "Candidacidal activity of recombinant human salivary histatin-5 and variants", pp. 50000-5007, 1996.
Murakami, Y. et al., "Inhibitory Effects of Synthetic Histidine-Rich Peptides on Haemagglutination by Bacteroides Gingivalis 381", Arch. Oral Biol., 35(9): 775-777 (1990).
Oppenheim, F.G. et al., "Histatins, a Novel Family of Histidine-Rich Proteins in Human Paretoid Secretion", J. Biol. Chem., 263 (16) :7472-7477 (Jun. 1988).
Xu, T. et al., "Anticandial Activity of Major Human Salivary Histatins", Infect. Immunol., 59 (8) :2549-2554 (Aug. 1991).
Xu, T. et al., "Anti-fungal Functional Domain of Histatin 3", J. Dent. Res. 70:497 (Apr. 1991).
Raj, P.A. et al., "Salivary Histatin 5: Depnedence of Sequence, Chain Length, and Helical Confirmation for Candidacidal Activity", J. Biol. Chem.,265 (7) :3898 (Mar. 15, 1990).
Santarpia III, R.P. et al.
Friden Phillip M.
Oppenheim Frank G.
Roberts F. Donald
Spacciapoli Peter
Xu Tao
Moore William W.
Periodontix, Inc.
Trustees of Boston University
Wax Robert A.
LandOfFree
Anti-fungal D-amino acid histatin-based peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-fungal D-amino acid histatin-based peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-fungal D-amino acid histatin-based peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2125479